Their relatively new CEO abruptly resigns (just one day before earnings report on Halloween yet!) amid squabble with a piggish board who should've been fired long ago.
They got raises while shareholders got nothing but large losses amid a biotech boom and roaring bull market at all-time highs.
Jim Cramer was right about this one.
No investor wants to invest in this company.
No institution wants this name on their books.
The damage is deep with no end in sight, but it begins with management and a pipeline.
I would like to tell you something you don't already know, but the same problem is still lingering as a gaping wound.
It's the same old destructive story.